株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多発性硬化症 : パイプライン製品の分析

Multiple Sclerosis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232855
出版日 ページ情報 英文 928 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.18円で換算しております。
Back to Top
多発性硬化症 : パイプライン製品の分析 Multiple Sclerosis - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 928 Pages
概要

多発性硬化症(MS)は、自身の免疫系が神経を覆う髄鞘(ミエリン)を攻撃する潜在的な消耗性疾患であり、ミエリンの損傷により、脳、脊髄、その他の部分の間のコミュニケーションが阻害されます。手足の麻痺、筋力低下、複視、霧視、刺痛または疼痛、疲労感、不明瞭発語などの症状があり、年齢、性別、家族歴、一部の感染症などが素因となります。

当レポートでは、世界における多発性硬化症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

多発性硬化症の概要

治療薬の開発

  • 多発性硬化症向けパイプライン製品:概要
  • 多発性硬化症向けパイプライン製品:比較分析

多発性硬化症:開発中の治療薬:企業別

多発性硬化症:開発中の治療薬:大学・研究機関別

多発性硬化症:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

多発性硬化症:開発中の製品:企業別

多発性硬化症:開発中の製品:大学・研究機関別

多発性硬化症:治療薬開発に従事している企業

多発性硬化症:治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 製品概要
  • 作用機序
  • R&Dの進捗

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8845IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 9, 30, 32, 173, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 46 and 2 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Multiple Sclerosis Overview
  • Therapeutics Development
  • Multiple Sclerosis - Therapeutics under Development by Companies
  • Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes
  • Multiple Sclerosis - Pipeline Products Glance
  • Multiple Sclerosis - Products under Development by Companies
  • Multiple Sclerosis - Products under Investigation by Universities/Institutes
  • Multiple Sclerosis - Companies Involved in Therapeutics Development
  • Multiple Sclerosis - Therapeutics Assessment
  • Drug Profiles
  • Multiple Sclerosis - Dormant Projects
  • Multiple Sclerosis - Discontinued Products
  • Multiple Sclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Sclerosis, H2 2016
  • Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2016
  • Multiple Sclerosis - Pipeline by 4D Pharma Plc, H2 2016
  • Multiple Sclerosis - Pipeline by AB Science SA, H2 2016
  • Multiple Sclerosis - Pipeline by AbbVie Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Abion Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Ablynx NV, H2 2016
  • Multiple Sclerosis - Pipeline by Abzena Plc, H2 2016
  • Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Actelion Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Adamas Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H2 2016
  • Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2016
  • Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H2 2016
  • Multiple Sclerosis - Pipeline by Alkermes Plc, H2 2016
  • Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H2 2016
  • Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2016
  • Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Aphios Corp, H2 2016
  • Multiple Sclerosis - Pipeline by Apitope International NV, H2 2016
  • Multiple Sclerosis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Arena Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by arGEN-X BV, H2 2016
  • Multiple Sclerosis - Pipeline by Argos Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
  • Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Astellas Pharma Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Asterias Biotherapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Athersys Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H2 2016
  • Multiple Sclerosis - Pipeline by Axxam SpA, H2 2016
  • Multiple Sclerosis - Pipeline by Baliopharm AG, H2 2016
  • Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by BioAegis Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by BioApex sro, H2 2016
  • Multiple Sclerosis - Pipeline by Biocad, H2 2016
  • Multiple Sclerosis - Pipeline by Biocon Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Biogen Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Biogenomics Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H2 2016
  • Multiple Sclerosis - Pipeline by Bioncotech Therapeutics SL, H2 2016
  • Multiple Sclerosis - Pipeline by Bionovis SA, H2 2016
  • Multiple Sclerosis - Pipeline by Bionure Farma SL, H2 2016
  • Multiple Sclerosis - Pipeline by Biovista Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H2 2016
  • Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Multiple Sclerosis - Pipeline by C4X Discovery Holdings PLC, H2 2016
  • Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Celgene Corp, H2 2016
  • Multiple Sclerosis - Pipeline by Cell Cure Neurosciences Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H2 2016
  • Multiple Sclerosis - Pipeline by Cellceutix Corp, H2 2016
  • Multiple Sclerosis - Pipeline by Cognosci Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Commence Bio Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Compugen Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc, H2 2016
  • Multiple Sclerosis - Pipeline by CuraVac Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Cyxone AB, H2 2016
  • Multiple Sclerosis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Eisai Co Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Eli Lilly and Company, H2 2016
  • Multiple Sclerosis - Pipeline by Endece LLC, H2 2016
  • Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H2 2016
  • Multiple Sclerosis - Pipeline by Evotec AG, H2 2016
  • Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Flex Pharma Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Forward Pharma A/S, H2 2016
  • Multiple Sclerosis - Pipeline by FPRT Bio Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Gemac SA, H2 2016
  • Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016
  • Multiple Sclerosis - Pipeline by GeNeuro SA, H2 2016
  • Multiple Sclerosis - Pipeline by Genzyme Corp, H2 2016
  • Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Multiple Sclerosis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Glialogix Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Hansa Medical AB, H2 2016
  • Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by HitGen LTD, H2 2016
  • Multiple Sclerosis - Pipeline by Humabs BioMed SA, H2 2016
  • Multiple Sclerosis - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Iltoo Pharma, H2 2016
  • Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Immune Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by ImmuNext Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Immungenetics AG, H2 2016
  • Multiple Sclerosis - Pipeline by Inception Sciences Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Kadimastem Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H2 2016
  • Multiple Sclerosis - Pipeline by KAHR medical Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Kancera AB, H2 2016
  • Multiple Sclerosis - Pipeline by Kareus Therapeutics SA, H2 2016
  • Multiple Sclerosis - Pipeline by Karo Pharma AB, H2 2016
  • Multiple Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by KPI Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Multiple Sclerosis - Pipeline by LFB SA, H2 2016
  • Multiple Sclerosis - Pipeline by Lipocure Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by MacroGenics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by MAKScientific LLC, H2 2016
  • Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals LLC, H2 2016
  • Multiple Sclerosis - Pipeline by MedAnnex Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by MedDay SA, H2 2016
  • Multiple Sclerosis - Pipeline by Medestea Research & Production SpA, H2 2016
  • Multiple Sclerosis - Pipeline by MedImmune LLC, H2 2016
  • Multiple Sclerosis - Pipeline by Merck KGaA, H2 2016
  • Multiple Sclerosis - Pipeline by Meta-IQ ApS, H2 2016
  • Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016
  • Multiple Sclerosis - Pipeline by MorphoSys AG, H2 2016
  • Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Neuralstem Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Neuronax SAS, H2 2016
  • Multiple Sclerosis - Pipeline by Neurotec Pharma SL, H2 2016
  • Multiple Sclerosis - Pipeline by New World Laboratories Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Novartis AG, H2 2016
  • Multiple Sclerosis - Pipeline by NovImmune SA, H2 2016
  • Multiple Sclerosis - Pipeline by Nuevolution AB, H2 2016
  • Multiple Sclerosis - Pipeline by Ogeda SA, H2 2016
  • Multiple Sclerosis - Pipeline by Omeros Corp, H2 2016
  • Multiple Sclerosis - Pipeline by OncoImmune Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Opexa Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H2 2016
  • Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H2 2016
  • Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Peptinov SAS, H2 2016
  • Multiple Sclerosis - Pipeline by Pfenex Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Pfizer Inc, H2 2016
  • Multiple Sclerosis - Pipeline by PharmaEssentia Corp, H2 2016
  • Multiple Sclerosis - Pipeline by PharmatrophiX Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Pharmaxis Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Pieris Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Polleo Pharma Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by ProNoxis AB, H2 2016
  • Multiple Sclerosis - Pipeline by Prothena Corp Plc, H2 2016
  • Multiple Sclerosis - Pipeline by Q Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H2 2016
  • Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Regenesance BV, H2 2016
  • Multiple Sclerosis - Pipeline by Renovo Neural Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Resverlogix Corp, H2 2016
  • Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H2 2016
  • Multiple Sclerosis - Pipeline by SanBio Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016
  • Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H2 2016
  • Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Symic Biomedical Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Synthon Holdings BV, H2 2016
  • Multiple Sclerosis - Pipeline by Targazyme Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Therapix Biosciences Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by TikoMed AB, H2 2016
  • Multiple Sclerosis - Pipeline by Toleranzia AB, H2 2016
  • Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H2 2016
  • Multiple Sclerosis - Pipeline by TxCell SA, H2 2016
  • Multiple Sclerosis - Pipeline by Vaccinex Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H2 2016
  • Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H2 2016
  • Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals Inc, H2 2016
  • Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H2 2016
  • Multiple Sclerosis - Pipeline by Xenetic Biosciences (UK) Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by XL-protein GmbH, H2 2016
  • Multiple Sclerosis - Pipeline by Yungjin Pharm Co Ltd, H2 2016
  • Multiple Sclerosis - Pipeline by Zenith Capital Corp, H2 2016
  • Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Multiple Sclerosis - Dormant Projects, H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..1), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..2), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..3), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..4), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..5), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..6), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..7), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..8), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..9), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..10), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..11), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..12), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..13), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..14), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..15), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..16), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..17), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..18), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..19), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..20), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..21), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..22), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..23), H2 2016
  • Multiple Sclerosis - Dormant Projects (Contd..24), H2 2016
  • Multiple Sclerosis - Discontinued Products, H2 2016
  • Multiple Sclerosis - Discontinued Products (Contd..1), H2 2016
  • Multiple Sclerosis - Discontinued Products (Contd..2), H2 2016
  • Multiple Sclerosis - Discontinued Products (Contd..3), H2 2016
  • Multiple Sclerosis - Discontinued Products (Contd..4), H2 2016

List of Figures

  • Number of Products under Development for Multiple Sclerosis, H2 2016
  • Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top